#JPM23 with Robert Nelsen: Our mot­to is 'do cool s@*t'

3 weeks ago

The con­fer­ence is back. What about the in­dus­try? Tak­ing the biotech pulse at #JPM23

3 weeks ago
Financing
In Focus

Gene ther­a­py side ef­fects prompt search for new de­liv­ery meth­ods

3 weeks ago
R&D
Cell/Gene Tx

Mod­er­na jumps in­to piv­otal pack with promis­ing RSV da­ta as big ri­vals face off in megablock­buster race

4 weeks ago
R&D

Drug name re­view: Sci­ence takes the spot­light in 2022

4 weeks ago
Pharma
Marketing

Scoop: Roche-backed start­up gives up on CD47, lays off all em­ploy­ees

4 weeks ago
People
Startups

Q&A: How to at­tract the eye of an ear­ly in­vestor in biotech R&D tools

4 weeks ago
Financing

As Il­lu­mi­na dis­ap­points Wall Street, com­peti­tors make their case at JPM

4 weeks ago
R&D

Flame Bio­sciences search­es for fu­ture af­ter No­var­tis flunks on canakinum­ab

4 weeks ago
Startups
R&D

Up­dat­ed: Roche, Io­n­is launch new Hunt­ing­ton’s dis­ease study

5 weeks ago
R&D

Q&A: Genen­tech's first mar­ket­ing chief Er­i­ca Tay­lor on lessons from the pan­dem­ic, and what's next for the Roche group

5 weeks ago
Pharma
Marketing

What we're see­ing at JPM so far: Up­com­ing BD moves, pipeline up­dates and more

5 weeks ago
Pharma

Scoop: Rakuten bil­lion­aire lines up $70M for pho­toim­munother­a­py

5 weeks ago
Financing
Startups

Ex­clu­sive: Eli Lil­ly boosts in­flam­ma­to­ry dis­ease pipeline, li­cens­es three can­di­dates from TRexBio

5 weeks ago
Deals

Scoop: MPM backs a new check­point in­hibitor biotech in $80M raise

Last month
Financing
Startups

Every drug ap­proved in 2022: A year of few­er new prod­ucts, but gene ther­a­py firsts and new block­busters

Last month
R&D
Special

Up­dat­ed: Off-the-shelf cell ther­a­py pi­o­neer Al­lo­gene re­cruits a Kite vet to run R&D

Last month
Bioregnum
R&D

Scoop: J&J-backed Aro Bio­ther­a­peu­tics eyes nine-fig­ure raise with first tri­al on hori­zon

Last month
Financing
Startups

Ex­clu­sive: In lieu of an IPO in rocky biotech mar­ket, Ap­n­imed lines up $80M from ex­ist­ing in­vestors for two PhI­II tri­als

Last month
Financing
Startups

Scoop: To fund Covid-19 nasal vac­cine boost­er, Yale spin­out snags Se­ries A

Last month
Financing
Startups

Trends for 2023: What's com­ing next in phar­ma mar­ket­ing and drug com­mer­cial­iza­tion?

Last month
Pharma
Marketing

Gilead­'s Kite nabs Carl June spin­out Tmu­ni­ty af­ter neu­ro­tox kills pa­tients, forc­ing re­org — and a re­think

Last month
Deals

Gilead and Ar­cus want you to be­lieve again in TIG­IT. But mixed ARC-7 da­ta are rolling out to a tough crowd

Last month
Bioregnum
R&D

Scoop: A2 Bio­ther­a­peu­tics rais­es $62M for sol­id tu­mor cell ther­a­pies

Last month
Financing
Startups
First page Previous page 12345 Next page Last page